Literature DB >> 19279101

Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.

Gail Ferstandig Arnold1, Paola K Velasco, Andrew K Holmes, Terri Wrin, Sheila C Geisler, Pham Phung, Yu Tian, Dawn A Resnick, Xuejun Ma, Thomas M Mariano, Christos J Petropoulos, John W Taylor, Hermann Katinger, Eddy Arnold.   

Abstract

In efforts to develop AIDS vaccine components, we generated combinatorial libraries of recombinant human rhinoviruses that display the well-conserved ELDKWA epitope of the membrane-proximal external region of human immunodeficiency virus type 1 (HIV-1) gp41. The broadly neutralizing human monoclonal antibody 2F5 was used to select for viruses whose ELDKWA conformations resemble those of HIV. Immunization of guinea pigs with different chimeras, some boosted with ELDKWA-based peptides, elicited antibodies capable of neutralizing HIV-1 pseudoviruses of diverse subtypes and coreceptor usages. These recombinant immunogens are the first reported that elicit broad, albeit modest, neutralization of HIV-1 using an ELDKWA-based epitope and are among the few reported that elicit broad neutralization directed against any recombinant HIV epitope, providing a critical advance in developing effective AIDS vaccine components.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19279101      PMCID: PMC2682058          DOI: 10.1128/JVI.00184-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  95 in total

1.  Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41.

Authors:  John M Louis; Carole A Bewley; Elena Gustchina; Annie Aniana; G Marius Clore
Journal:  J Mol Biol       Date:  2005-09-30       Impact factor: 5.469

2.  Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate.

Authors:  Nobuyuki Matoba; Brian C Geyer; Jacquelyn Kilbourne; Annette Alfsen; Morgane Bomsel; Tsafrir S Mor
Journal:  Vaccine       Date:  2006-03-30       Impact factor: 3.641

3.  Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.

Authors:  Ling Ye; Yuliang Sun; Jianguo Lin; Zhigao Bu; Qingyang Wu; Shibo Jiang; David A Steinhauer; Richard W Compans; Chinglai Yang
Journal:  Virology       Date:  2006-05-24       Impact factor: 3.616

4.  Lack of neutralizing antibody response to HIV-1 predisposes to superinfection.

Authors:  Davey M Smith; Matthew C Strain; Simon D W Frost; Satish K Pillai; Joseph K Wong; Terri Wrin; Yang Liu; Christos J Petropolous; Eric S Daar; Susan J Little; Douglas D Richman
Journal:  Virology       Date:  2006-09-07       Impact factor: 3.616

5.  Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.

Authors:  Martine Braibant; Sylvie Brunet; Dominique Costagliola; Christine Rouzioux; Henri Agut; Hermann Katinger; Brigitte Autran; Francis Barin
Journal:  AIDS       Date:  2006-10-03       Impact factor: 4.177

6.  Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.

Authors:  Steven G Deeks; Becky Schweighardt; Terri Wrin; Justin Galovich; Rebecca Hoh; Elizabeth Sinclair; Peter Hunt; Joseph M McCune; Jeffrey N Martin; Christos J Petropoulos; Frederick M Hecht
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

7.  Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).

Authors:  Beda Joos; Alexandra Trkola; Herbert Kuster; Leonardo Aceto; Marek Fischer; Gabriela Stiegler; Christine Armbruster; Brigitta Vcelar; Hermann Katinger; Huldrych F Günthard
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

8.  Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.

Authors:  Min Luo; Fei Yuan; Yanxia Liu; Siming Jiang; Xijun Song; Pengfei Jiang; Xiaolei Yin; Mingxiao Ding; Hongkui Deng
Journal:  Vaccine       Date:  2005-08-18       Impact factor: 3.641

9.  Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.

Authors:  Eloisa Yuste; Hannah B Sanford; Jill Carmody; Jacqueline Bixby; Susan Little; Michael B Zwick; Tom Greenough; Dennis R Burton; Douglas D Richman; Ronald C Desrosiers; Welkin E Johnson
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

10.  Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1.

Authors:  Francis Barin; Gonzague Jourdain; Sylvie Brunet; Nicole Ngo-Giang-Huong; Supawadee Weerawatgoompa; Warit Karnchanamayul; Surabhon Ariyadej; Rawiwan Hansudewechakul; Jullapong Achalapong; Prapap Yuthavisuthi; Chaiwat Ngampiyaskul; Sorakij Bhakeecheep; Chittaphon Hemwutthiphan; Marc Lallemant
Journal:  J Infect Dis       Date:  2006-04-21       Impact factor: 5.226

View more
  39 in total

1.  Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7.

Authors:  Jerri do Carmo Caldeira; Alexander Medford; Rhonda C Kines; Christopher A Lino; John T Schiller; Bryce Chackerian; David S Peabody
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

2.  Elicitation of structure-specific antibodies by epitope scaffolds.

Authors:  Gilad Ofek; F Javier Guenaga; William R Schief; Jeff Skinner; David Baker; Richard Wyatt; Peter D Kwong
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

Review 3.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

4.  Developing strategies to enhance and focus humoral immune responses using filamentous phage as a model antigen.

Authors:  Kevin A Henry; Armstrong Murira; Nienke E van Houten; Jamie K Scott
Journal:  Bioeng Bugs       Date:  2011-09-01

5.  Immunization with hybrid proteins containing the membrane proximal external region of HIV-1.

Authors:  Nicola Strasz; Vladimir A Morozov; Jürgen Kreutzberger; Martina Keller; Magdalena Eschricht; Joachim Denner
Journal:  AIDS Res Hum Retroviruses       Date:  2014-02-07       Impact factor: 2.205

6.  Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.

Authors:  Susan Zolla-Pazner; Rebecca Powell; Sara Yahyaei; Constance Williams; Xunqing Jiang; Wei Li; Shan Lu; Shixia Wang; Chitra Upadhyay; Catarina E Hioe; Max Totrov; Xiangpeng Kong
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

Review 7.  Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.

Authors:  Qiana L Matthews
Journal:  Mol Pharm       Date:  2010-12-01       Impact factor: 4.939

8.  Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.

Authors:  Jean-Philippe Julien; Nerea Huarte; Rubén Maeso; Stefka G Taneva; Annie Cunningham; José L Nieva; Emil F Pai
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

9.  Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies.

Authors:  Jinsong Zhang; S Munir Alam; Hilary Bouton-Verville; Yao Chen; Amanda Newman; Shelley Stewart; Frederick H Jaeger; David C Montefiori; S Moses Dennison; Barton F Haynes; Laurent Verkoczy
Journal:  J Immunol       Date:  2014-01-24       Impact factor: 5.422

10.  Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses.

Authors:  Rui Gu; Anae Shampang; Toufic Nashar; Manisha Patil; Deborah H Fuller; Arlene I Ramsingh
Journal:  PLoS One       Date:  2010-09-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.